Change in Newborn Eligibility and Claims Processing

Recently the Department of Health Care Services (DHCS) changed the way newborn eligibility is processed. Newborns now receive an Identification Number (ID#) within 2 weeks of birth. When billing for a newborn, use the newborn’s ID# if it has been issued and indicate “self” as the relationship. If it has not been issued, bill with the mother’s ID# and indicate “child” as the relationship.

Eligibility can be checked via our website at www.cencalhealth.org or by calling the CenCal Health Eligibility Verification Line at 1 (877) 814 -1861; option 3.

Importance of Fluoride Varnish Benefit

As a reminder, Fluoride Varnish is a covered benefit for eligible children enrolled in the Santa Barbara Health Initiative (SBHI) and San Luis Obispo Health Initiative (SLOHI). By applying fluoride varnish, medical providers (i.e. Pediatricians, RNs, and Medical Assistants) have an opportunity to help prevent tooth decay, which remains one of the most common chronic diseases of childhood. The application does not require special equipment and it is more practical to use with young children. For staff trainings or other questions in Santa Barbara County, please contact Mary Ellen Rehse, Oral Health Program Manager at mrehse@sbceo.org or call (805) 964.4711 X 4465. For staff trainings or other questions in San Luis Obispo County, please contact our Quality Improvement Department at (805) 617-1997.

Billing for Fluoride Varnish

- Use HCPCS code D1206 or CPT code 99188 - topical application of fluoride
- Reimbursement includes all materials and supplies needed for the application
- Applications must be documented in the member's medical record
- Treatment is covered up to 3 times in a 12-month period for children age 0 to 5
- Preauthorization is not required

Please contact the CenCal Health Claims Department regarding claims and billing at (805) 562-1083.

Claims Corner

Tips, news, & more.

Billing for Postpartum Care

Reminder CenCal Health requires a separate claim for postpartum care reimbursement if you are billing globally for obstetrical care. Once a member receives their postpartum visit, you can bill using the code Z1038 for postpartum care. The reimbursement for this visit is not included in the global billing reimbursement so be sure to bill for this important service.

If you have any questions please contact our Claims Department at (805) 562-1083.
On The Horizon: Provider Training Opportunities

CenCal Health will be hosting a variety of training opportunities, these events are focused on supporting provider staff on a variety of subjects designed to enhance the quality of care and services our members receive.

Upcoming Training Event:

Webinars

• **Authorization Webinar, Thursday, April 20th, 2017**
  *Understand the importance of authorizations and how to submit them for quick approval*

• **CenCal Health Website Tour, Thursday, May 18th, 2017**
  *Learn where to find our most important items on our website along with provider reference tools*

Seminars

• **Keeping our Kids Health Seminar, May 9th –11th, 2017**
  *Important Tips to Improve Child and Teen Health and Prevent Disease*

• **Understanding Denials & Submitting Corrections, June 6th -8th, 2017**
  *Learn about our Top Ten Common Denials and when to submit a dispute vs. an appeal*

Please visit our website at [http://www.cencalhealth.org/providers/provider-training-resources/](http://www.cencalhealth.org/providers/provider-training-resources/) to view a list of additional upcoming educational opportunities or contact our Provider Services Education Specialist at (805) 562-1671.

Formulary Update - Preferred Long-Acting Insulin

Effective April 1, 2017, Basaglar® (insulin glargine) will be the preferred long-acting (basal) insulin on the CenCal Health Formulary. Lantus®, Lantus® SoloStar, Levemir®, Levemir® FlexTouch, and Toujeo® SoloStar will be removed from the CenCal Health formulary. Members who are adherent to their Levemir®, Levemir® FlexTouch, and Toujeo® SoloStar regimen prior to April 1, 2017 will not be required to switch to the preferred agent. All members on Lantus® and Lantus® SoloStar will be required to switch to the preferred agent. This change will affect all physicians.

CenCal Health and its Pharmacy Benefits Manager, MedImpact are working together to communicate patient-specific prescription medication use to both members and providers. In an effort to minimize member and provider disruption, beginning 4/1/17 providers who have patients on Lantus® and Lantus® SoloStar will receive a Prescription Change Form via fax asking providers to authorize a new prescription. The form will serve as a valid order to begin dispensing the new medication with the next routine prescription fill. If the Prescription Change Form is not completed and faxed to MedImpact then a MRF will need to be submitted for medical necessity for all non-preferred agents beginning June 1, 2017.

Basaglar® Facts:

- Basaglar® is insulin glargine
- Basaglar® is available ONLY as a KwikPen, a disposable prefilled pen
- Basaglar® can dispense 1 to 80 Units in a single injection
- Basaglar® requires the same pen needles as Lantus® Solostar
- Per the FDA, Basaglar® is considered a “follow-on” to Lantus® and not a generic
- Basaglar® will require a new prescription.

Please contact CenCal Health Pharmacy Department with questions and concerns at (805) 562-1080